Author:
Cantera Jason L.,Lillis Lorraine M.,Peck Roger B.,Moreau Emmanuel,Schouten James A.,Davis Paul,Drain Paul K.,Andama Alfred,Pinter Abraham,Kawasaki Masanori,Källenius Gunilla,Sundling Christopher,Dobos Karen M.,Flores Danara,Chatterjee Delphi,Murphy Eileen,Halas Olivia R.,Boyle David S.
Abstract
AbstractLipoarabinomannan (LAM), a component of the Mycobacterium tuberculosis (MTB) cell wall, is detectable in the urine of MTB infected patients with active tuberculosis (TB). LAM-specific antibodies (Igs) have been developed by a variety of traditional and recombinant methods for potential use in a rapid diagnostic test (RDT). We evaluated the analytical performance of the TB LAM Igs to identify pairs that offer superior performance over existing urine LAM tests. We assessed 25 new and 4 existing Igs in a matrixed format using a multiplex electrochemiluminescence-based liquid immunoassay. A total of 841 paired Ig combinations were challenged with in vitro cultured LAM (cLAM) derived from MTB strains representing diverse phylogenetic lineages, alongside urinary LAM (uLAM) from the urine of adults with active pulmonary TB. Analytical sensitivity of down-selected Ig pairs was determined using MTB Aoyama-B cLAM, while diagnostic accuracy was determined using clinical samples. When testing cLAM, the reactivity of Ig pairs was similar across MTB lineages 1-4 but lineage 5:6 had significantly more reactivity among Ig pairs. Overall, 41 Ig pairs had a strong binding affinity to cLAM, as compared to the reference pair of S4-20/A194-01, and 28 Ig pairs therein exhibited a strong affinity for both cLAM and uLAM. Retrospective testing on clinical urine specimens demonstrated varying sensitivities (12-80%) and specificities (14-100%). The five top pairs had a similar analytical limit of detection to the reference pair but in four instances, the sensitivity and specificity with clinical uLAM samples was poor. Overall, epitopes presented by uLAM are different from cLAM, which may affect antibody performance when testing uLAM in patient samples. Several new Ig pairs had similar ranges of high sensitivity to cLAM but overall, there were no new candidate Ig pairs identified in this round of screening with increased performance with uLAM as compared to an existing optimal pair.
Publisher
Cold Spring Harbor Laboratory
Reference44 articles.
1. World Health Organization. Global Tuberculosis Report 2021. p. 57. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021
2. Location, location, location: tuberculosis services in highest burden countries;Lancet Glob Health,2016
3. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence
4. Comparison of scanty AFB smears against culture in an area with high HIV prevalence;Int J Tuberc Lung Dis,2005
5. Understanding the incremental value of novel diagnostic tests for tuberculosis;Nature,2015